Rheumatic immune-related adverse events of checkpoint therapy for cancer

Update: 2017-12-06

Description

Cassandra Calabrese (Cleveland Clinic Foundation, Ohio, USA) speaks with Editor-in-Chief of RMD Open Bernard Combe about checkpoint inhibitors.
For more information, please visit the RMD Open website, where the related article to this podcast can also be found:

Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity: http://rmdopen.bmj.com/content/3/1/e000412.

Comments

In Channel

Promoting gender equity in academic rheumatology

2023-02-2129:04

Autoantibodies against PTM proteins as biomarkers for lupus

2023-01-1309:46

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

2022-07-1517:10

Air pollution associated with higher risk of developing autoimmune diseases

2022-06-0118:44

COVID-19 and cytokines - same storm, different origins?

2020-06-1011:02

Imaging in large vessel vasculitis

2018-11-0909:15

The use of MRI in rheumatology

2018-09-1803:25

Improving the peer review skills of young researchers in rheumatology

2018-08-1011:02

Don’t neglect nutrition in rheumatoid arthritis!

2018-06-1306:36

A standardised catalogue of patient scenarios to improve the ranking of RA disease activity?

2018-05-1818:44

Osteoarthritis or rheumatoid? The MDHAQ patient questionnaire role in routine rheumatology care

2018-03-1306:08

Sjögren’s syndrome: what do we know so far?

2018-01-2505:14

Rheumatic immune-related adverse events of checkpoint therapy for cancer

2017-12-0605:56

Branded drug or biosimilar? Reasons to adopt generics in rheumatology, by Professor Jonathan Kay

2017-11-0605:17

Early diagnosis and treatment: the Rheumatic Diseases Portuguese Register

2017-07-1705:39

Interleukin-17: a role in inflammatory arthritis and implication for clinical practice

2017-05-0513:34

Welcome to RMD Open

2015-02-0405:39

00:00

Rheumatic immune-related adverse events of checkpoint therapy for cancer

#box-pro-ellipsis-17601907048713{-webkit-line-clamp:2;}Rheumatic immune-related adverse events of checkpoint therapy for cancer

Rheumatic immune-related adverse events of checkpoint therapy for cancer

BMJ Group

Rheumatic immune-related adverse events of checkpoint therapy for cancer